Skip to main content
Erschienen in: Supportive Care in Cancer 5/2024

Open Access 01.05.2024 | Review

The use of interventional procedures for cancer pain. A brief review

verfasst von: Yi-Ching Lee, Timothy Brake, Emma Zhao, Alix Dumitrescu, Wei Lee, Benjamin Tassie, Kok-Eng Khor, Andy Yi-Yang Wang

Erschienen in: Supportive Care in Cancer | Ausgabe 5/2024

Abstract

Context

Pain is a common experience in people living with cancer. Concerns around opioid prescribing have seen a move toward a multi-modality management approach, which includes interventional pain procedures.

Purpose

In this paper we discuss the interventional pain procedures used to treat cancer pain at two major tertiary centers in Australia.

Methods and results

This expert review provides practical insights on cancer pain management from healthcare providers in different specialties. These insights can be used to guide the management of a wide range of cancer pain types.

Conclusions

Furthermore, this review identifies the need for a systematic and comprehensive approach to the management of cancer pain that is broader than that of a single specialty. With recent advances in pain management procedures, an interdisciplinary approach is essential in order to provide an up to date, patient tailored approach to pain management.
This review will help inform the development of a cancer pain intervention registry.
Hinweise

Relevance of manuscript to inform research, policies, and/or programs

This study describes the types of interventional approaches used in cancer pain management. Further work is required to understand the types of patients that access this type of pain management and barriers to care.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Cancer pain

Pain is a common experience in people living with cancer; up to 80% of patients with advanced cancer experience pain [1]. Studies showed that more than one third of individuals report moderate to severe pain and up to 10% of patients experience chronic severe pain [2]. Cancer pain can be attributed to the malignancy, its complications, or side effects of treatments (e.g., post-surgical pain and chemotherapy-induced peripheral neuropathy) [3, 4]. The underlying pathogenesis may involve not only the nociceptive mechanism caused by ongoing tissue damage, but also neuropathic and sensitization processes caused by atypical somatosensory processing in the peripheral or central nervous systems [4, 5].
In 1985, the World Health Organization proposed the analgesic ladder [6], which supported commencing the treatment of cancer pain with non-opioid medications, before progressing to weak opioids followed lastly by strong opioids. However, both the opioid crisis and the fact that patients can become unresponsive to strong opioids necessitated the re-examination of the use of opioids in the treatment of pain, including cancer pain [7, 8]. The analgesic ladder has subsequently been modified over time, with Vargas-Schaffer suggesting the inclusion of a fourth step which added invasive techniques to the pain management armament (Fig. 1) [8, 9].
With both advances in imaging technology and a better understanding of cancer pain pathogenesis, there has been growing utilization of interventional techniques in the management of cancer pain. The use of advanced imaging modalities has facilitated more and more accurate target localization with less invasive techniques than in the past. In the last few decades, interventions relied initially on landmarks and later on two-dimensional fluoroscopy with X-ray guidance. With growing availability and portability of CT scans, much better precision is achievable with three-dimensional real-time visualization. It also further facilitates treatment of smaller structures such as spinal nerve targets and allows better localization of structures in those with difficult anatomy due to prior surgical procedures or presence of malignancy distorting normal anatomy.

Pain prevention

All patients undergoing cancer treatment should undergo prehabilitation strategies, where possible [10]. Total body prehabilitation can improve post-operative pain. For example, psychological prehabilitation prior to surgery can reduce post-operative pain in people undergoing breast surgery [11], and pre-operative exercise programs in this setting may also reduce post operative pain [12].

Interventional pain procedures

Interventional pain procedures refer to treatments directly applied on a neuraxial region, autonomic nerve plexuses, or peripheral nerves [13]. This may involve the delivery of a drug (often with local anesthetic or neurolytic agents), modulation of nerve transmission through electrical impulses with radiofrequency ablation device or use of spinal cord stimulator, or destructive procedures such as cordotomy [13, 14]. However, apart from celiac plexus blocks, high-quality evidence supporting the use of most of these procedures is lacking, with most evidence derived from retrospective studies or case series conducted in single health institution [1518].
Here we explore the range of interventional procedures performed in two major cancer centers in New South Wales, Australia. The interventional pain procedures used to treat cancer pain are outlined in Table 1.
Table 1
Potential categories for intervention
Nerve block and neurolysisa
Peripheral nerve
Nerve plexus
Neuraxial
-Epidural and intrathecal interventions (e.g. saddle block)
-Percutaneous cervical cordotomy
Implantable devices
Targeted drug delivery (e.g. intrathecal pump)
Nerve stimulators (targeting spinal cord and/or peripheral nerve)
Surgical options (minimally invasive and open techniques)
Bilateral open thoracic cordotomies
Dorsal root entry zone lesioning procedures
Radiological options
Vertebroplasty
Emerging options
Percutaneous trans-arterial embolization
aNerve blocks use local anesthetic solutions and have a temporary effect; neurolysis uses destructive agents such as alcohol or phenol to destroy the affected tissues and nervous structures

Peripheral nerve blocks

Peripheral nerve blocks work by interrupting nociceptive transmission from a regional nerve innervating the painful structure by use of a local anesthetic injection. Common applications include intercostal nerve blocks for rib pain from bony metastasis, trigeminal nerve blocks for head and neck malignancy, femoral/sciatic nerve blocks for lower limb pain, or serratus anterior blocks for chest wall pain following mastectomy or thoracic surgery. For longer duration of effect lasting from days to weeks, an indwelling catheter for repeated bolus doses or continuous infusion may be considered.
In patients with progressive pain, neurolytic blocks with injection of alcohol or phenol are often the intervention of choice for their more definitively destructive mechanism on affected tissues and nervous structures [19, 20]. The main concerns of peripheral nerve neurolysis include neuritis, painful dysesthesia, or deafferentation pain worsening existing symptoms, and motor weakness or bowel/bladder incontinence if motor/autonomic nerves are involved [19, 20]. The effectiveness and rate of adverse events with peripheral nerve intervention in cancer pain management require further evaluation as most evidence has been derived from case series [19, 20].

Nerve plexus/sympathetic blocks

Interruption of afferent or sympathetic nerve pathways forms the basis for analgesia in relevant body parts. Visceral afferent nociception from cancer involving upper abdominal structures such as the pancreas, liver, stomach, adrenals and kidneys travels through the celiac plexus and then through the splanchnic nerves to the central nervous system.
For lower abdominal and pelvic structures such as the bladder, prostate, sigmoid colon, uterus, ovaries, vaginal fundus, and rectum, the afferent nociceptive signals pass through the superior hypogastric plexus. For perineal structures such as the anus, distal rectum, urethra, scrotum, vulva, and vagina, afferent signals pass through the ganglion impar (ganglion of Walther) located on the anterior surface of the sacrum at the sacrococcygeal junction [21].
Among cancer pain interventions, celiac plexus block and neurolysis have been most heavily studied, and their use has been largely supported by randomized controlled trials and systematic review for analgesic efficacy [22, 23]. Most of the evidence, however, draws on the early studies using a percutaneous fluoroscopy guided approach. Later studies demonstrated non-inferiority from ultrasound-guided modality [24]. Advancing techniques has seen the increasing utilization of CT guided approach to provide three-dimensional visualization of needle placement [25] (Figs. 2 and 3). These advances necessitate the involvement of an interventional radiologist in the interdisciplinary team.
Other sympathetic blocks that can be performed include stellate ganglion blocks for managing pain in the head and neck, breast, and upper limb region and also lumbar sympathetic blocks for sympathetically maintained lower limb pain [26, 27]. Similarly, randomized controlled studies that assess these are lacking in the literature. Splanic nerve block with fluoroscopy/X-ray guidance is shown in  Fig. 4.

Intrathecal analgesia

Intrathecal analgesia involves the delivery of medication into cerebrospinal fluid in the vicinity of the intended spinal level/s . Intrathecal drug delivery has been increasingly utilized over the last few decades in patients with cancer that does not respond to conventional medical management or where there are intolerable side-effects systemic analgesic agents. The use of intrathecal opioid analgesia is well supported by reviews on safety, pain reduction, and cost-effectiveness and may be supplemented with other agents off label including local anesthetics or clonidine [28, 29].
The drug/s may be delivered through a single bolus injection, through external infusion pump, or a fully implantable device. The choice of delivery method depends largely on the clinical situation and local nursing expertise and availability. External infusion pumps are usually considered for patients with a limited prognosis measured in weeks, whereas fully implantable devices are more appropriate for patients with a life expectancy greater than 6 months [28, 29].
For cancer patients with poor prognosis and poor functional status, a saddle block, involving administration of neurolytic agents such as alcohol or phenol, can be a helpful procedure for perineal pain. It produces a more prolonged clinical effect at the expense of motor and autonomic functions [28, 29]. Careful patient positioning by an experienced interventionalist is essential, for example sitting with a slight backwards lean when using heavy phenol or in the prone Trendelenburg position when using hypobaric alcohol to avoid spreading to adjacent sensorimotor nerves.
The other potential intervention includes use of a spinal cord stimulator by placement of an electrical lead in the epidural space [30]. However, apart from an associated reduction in opioid use, there is very limited evidence of effectiveness in the management of cancer pain [30].

Cordotomy

Cordotomy is an ablative procedure of the spinal cord (predominately the spinothalamic tract) performed almost exclusively for cancer-related pain. Unilateral percutaneous cordotomy with entry at the level of C1/2 on the contralateral side to the pain is the most common approach, although it can also be performed endoscopically, transdiscally, or as an open procedure [31].
Percutaneous cordotomy requires the patient to be awake and cooperative to allow for sensory stimulation and feedback, whereas the open procedure is done under general anesthesia (Fig. 5). Percutaneous cordotomy is indicated for those with poorly controlled unilateral pain (below the level of the C4 dermatome) and with an estimated prognosis of less than 6 to 12 months [32]. The overall complication rates with CT guidance are low, with severe respiratory compromise and motor weakness being the major concerns.
For those with axial pain below the diaphragm, a bilateral thoracic cordotomy is more appropriate [18]. This requires the expertise of neurosurgeons as an open procedure. Similarly, its use is supported by many case series [33, 34].

Radiofrequency ablation

Radiofrequency ablation is a high temperature thermal therapy that induces coagulation necrosis [35]. It is performed under image guidance and is a useful treatment particularly for patients with painful vertebral metastases [36].

Vertebroplasty

Vertebroplasty involves the injection of artificial bone cement and an opacifier into the inter-trabecular marrow space of fractured vertebrae [37]. It is performed with imaging guidance under local anesthesia [37, 38]. It is useful for painful vertebral compression fractures caused by metastases or multiple myeloma [37, 38] and can be used in patients receiving adjuvant radiation, surgical therapy, or chemotherapy [37]. In Australia, vertebroplasty is performed infrequently due to its invasive nature and lack of clear evidence of its benefit.

Trans-arterial embolization

Trans-arterial embolization involves the injection of embolic agents in the arteries supplying the tumor and is well known for management of spinal bone lesions. There is emerging evidence, primarily based on retrospective studies, demonstrating the potential benefits for treatment of painful bony metastases refractory to conventional radiotherapy [39, 40].

Barriers to cancer pain management

It has long been recognized that cancer pain is undertreated, despite the availability of evidence-based guidelines. An Australian survey of palliative care specialists (n = 92) identified the following barriers to the provision of pain management: insufficient access to nonpharmacologic interventions, patient comorbidities, and a lack of coordination between services [41]. A systematic review of service delivery models for cancer pain recommended the development of policies for referrals to a pain consultation service which can be integrated into a clinical pathway [42]. This would help to address the lack of coordination between services.
A recent qualitative study to identify barriers and facilitators of interventional management of cancer pain interviewed healthcare professionals (n=24) involved in cancer care at two cancer centers in Sydney (unpublished). The study identified six themes, which overlapped with the previous findings. These were (1) clinicians’ knowledge and awareness of interventional pain management, (2) training and resources on interventional pain procedures, (3) unclear referral pathways, (4) clinician perceptions of safety and efficacy, (5) the timing of the intervention, and (6) the need for holistic healthcare. Anecdotally, clinical practices appear to vary significantly due to different expertise and institutional preferences.
A broader review of barriers to optimal cancer pain management identified not only clinician barriers but also society’s attitude toward pain management, system barriers, patient barriers, and healthcare disparities [43]. With regard to healthcare disparities, we know that cancer incidence is higher in New South Wales, Australia outside of the major cities, of which Sydney is one [44]. It is highly likely that access to interventional pain management approaches are limited for patients living with cancer in regional and remote parts of Australia.
Another older Australian study explored patient barriers to optimal pain management. It identified three barriers: (1) poor levels of patient knowledge about pain, (2) low perceived control over pain, and (3) a lack of communication about pain [45]. Without knowing more about how cancer pain is currently being managed it is hard to suggest strategies to overcome these barriers. However, patient education about pain management should not be discounted.

Chronic pain

As cancer survivorship improves, it is important to be aware of the possibility of chronic pain. Cancer survivors often experience adverse physical and psychosocial effects from the diagnosis and its treatment, and should not be overlooked when taking a chronic pain management approach [46, 47]. Cancer survivors with chronic pain also report lack of sleep, fatigue, and mental health issues [47]. In our experience some cancer survival present for repeated interventional pain management procedures, for example, intercostal radiofrequency ablation for persistent post-mastectomy, or post sternotomy pain [48]. Cancer survivors should be assessed and be appropriately referred for treatment of chronic pain, where appropriate. Currently there is very limited evidence to specifically address chronic pain issues in this unique population, and more research into effective strategies is needed.

The need for a cancer pain intervention registry

This review shows the wide range of pain intervention procedures that are currently used in the management of cancer pain. However, to date, there is deficiency of evidence in specific applications, indications, efficacy, or adverse events for varying interventions in treatment of cancer pain. The most recent cancer incidence data for New South Wales, Australia showed 48,165 new cancer diagnoses in 2020 [49]. People are living with cancer for longer than ever before [50], and over one third of cancer patients report moderate to severe cancer pain [2], so the need to understand best practices in cancer pain management is growing.
The establishment of a national cancer pain intervention registry should be considered. This would provide insight into the different interventional pain procedures used in patients with cancer, how these procedures are accessed, their perceived efficacy, and geographical variation. Such a registry would also capture information about the roles and involvement of the interdisciplinary team in the successful management of cancer pain.

Conclusions

This review has provided an overview of interventions used in the management of cancer pain through leading clinicians in the field of pain management and palliative care. It identified need for better evidence guiding future practice, in particular, through establishment of an intervention registry. It also pointed out barriers in achieving optimal pain management, which included lack of co-ordination of suitable interventional pain management in the heterogenous cancer population as one major issue.

Acknowledgements

The authors thank Pippa Burns, PhD, CMPP of WriteSource Medical Pty Ltd, Sydney, Australia, for providing medical writing support. Medical writing support was funded by Chris O’Brien Lifehouse SurFebruary Cancer Research Fund in accordance with Good Publication Practice (GPP2022) guidelines (https://www.acpjournals.org/doi/10.7326/M22-1460).

Declarations

Competing interests

The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Relevance of manuscript to inform research, policies, and/or programs

This study describes the types of interventional approaches used in cancer pain management. Further work is required to understand the types of patients that access this type of pain management and barriers to care.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Jetzt e.Med zum Sonderpreis bestellen!

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt bestellen und 100 € sparen!

Literatur
1.
Zurück zum Zitat Haumann J, Joosten EBA, van den Beuken-van MH (2017) Pain prevalence in cancer patients: status quo or opportunities for improvement? Curr Opin Support Palliat Care 11(2):99–104CrossRefPubMed Haumann J, Joosten EBA, van den Beuken-van MH (2017) Pain prevalence in cancer patients: status quo or opportunities for improvement? Curr Opin Support Palliat Care 11(2):99–104CrossRefPubMed
4.
Zurück zum Zitat Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M et al (2018) Management of cancer pain in adult patients: ESMO clinical practice guidelines. Ann Oncol 29:iv166–iiv91CrossRefPubMed Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M et al (2018) Management of cancer pain in adult patients: ESMO clinical practice guidelines. Ann Oncol 29:iv166–iiv91CrossRefPubMed
6.
Zurück zum Zitat Ventafridda V, Saita L, Ripamonti C, De Conno F (1985) WHO guidelines for the use of analgesics in cancer pain. Int J Tissue React 7(1):93–96PubMed Ventafridda V, Saita L, Ripamonti C, De Conno F (1985) WHO guidelines for the use of analgesics in cancer pain. Int J Tissue React 7(1):93–96PubMed
9.
Zurück zum Zitat Vargas-Schaffer G (2010) Is the WHO analgesic ladder still valid? Twenty-four years of experience. Can Fam Physician 56:514–517PubMedPubMedCentral Vargas-Schaffer G (2010) Is the WHO analgesic ladder still valid? Twenty-four years of experience. Can Fam Physician 56:514–517PubMedPubMedCentral
10.
Zurück zum Zitat Dawson S, Koneti KK (2022) The role of pain management in cancer prehabilitation. In: Chakraborty A, Balakrishnan A (eds) Prehabilitation for cancer surgery. Springer Nature Singapore, Singapore, pp 217–247CrossRef Dawson S, Koneti KK (2022) The role of pain management in cancer prehabilitation. In: Chakraborty A, Balakrishnan A (eds) Prehabilitation for cancer surgery. Springer Nature Singapore, Singapore, pp 217–247CrossRef
13.
Zurück zum Zitat Joshi M, Chambers WA (2010) Pain relief in palliative care: a focus on interventional pain management. Expert Rev Neurother 10(5):747–756CrossRefPubMed Joshi M, Chambers WA (2010) Pain relief in palliative care: a focus on interventional pain management. Expert Rev Neurother 10(5):747–756CrossRefPubMed
14.
Zurück zum Zitat Koyyalagunta D, Simmonds MJ, Novy DM (2019) General pain management concepts. In: Gulati A, Puttanniah V, Bruel BM, Rosenberg WS, Hung JC (eds) Essentials of interventional cancer pain management. Springer, Cham, pp 47–54CrossRef Koyyalagunta D, Simmonds MJ, Novy DM (2019) General pain management concepts. In: Gulati A, Puttanniah V, Bruel BM, Rosenberg WS, Hung JC (eds) Essentials of interventional cancer pain management. Springer, Cham, pp 47–54CrossRef
15.
Zurück zum Zitat Stearns LJ, Narang S, Albright RE, Hammond K, Xia Y, Richter HB et al (2019) Assessment of health care utilization and cost of targeted drug delivery and conventional medical management vs conventional medical management alone for patients with cancer-related pain. JAMA Netw Open 2(4):e191549–e19154eCrossRefPubMedPubMedCentral Stearns LJ, Narang S, Albright RE, Hammond K, Xia Y, Richter HB et al (2019) Assessment of health care utilization and cost of targeted drug delivery and conventional medical management vs conventional medical management alone for patients with cancer-related pain. JAMA Netw Open 2(4):e191549–e19154eCrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Hung JC, Azam N, Puttanniah V, Malhotra V, Gulati A (2014) Neurolytic transversus abdominal plane block with alcohol for long-term malignancy related pain control. Pain Physician 17(6):E755–EE60CrossRefPubMed Hung JC, Azam N, Puttanniah V, Malhotra V, Gulati A (2014) Neurolytic transversus abdominal plane block with alcohol for long-term malignancy related pain control. Pain Physician 17(6):E755–EE60CrossRefPubMed
17.
Zurück zum Zitat Vayne-Bossert P, Afsharimani B, Good P, Gray P, Hardy J (2016) Interventional options for the management of refractory cancer pain—what is the evidence? Support Care Cancer 24:1429–1438CrossRefPubMed Vayne-Bossert P, Afsharimani B, Good P, Gray P, Hardy J (2016) Interventional options for the management of refractory cancer pain—what is the evidence? Support Care Cancer 24:1429–1438CrossRefPubMed
20.
Zurück zum Zitat Klepstad P, Kurita GP, Mercadante S, Sjøgren P (2015) Evidence of peripheral nerve blocks for cancer-related pain: a systematic review. Minerva Anestesiol 81(7):789–793PubMed Klepstad P, Kurita GP, Mercadante S, Sjøgren P (2015) Evidence of peripheral nerve blocks for cancer-related pain: a systematic review. Minerva Anestesiol 81(7):789–793PubMed
24.
Zurück zum Zitat Bhatnagar S, Joshi S, Rana SP, Mishra S, Garg R, Ahmed SM (2014) Bedside ultrasound-guided celiac plexus neurolysis in upper abdominal cancer patients: a randomized, prospective study for comparison of percutaneous bilateral paramedian vs. unilateral paramedian needle-insertion technique. Pain Pract 14(2):E63–E68. https://doi.org/10.1111/papr.12107CrossRefPubMed Bhatnagar S, Joshi S, Rana SP, Mishra S, Garg R, Ahmed SM (2014) Bedside ultrasound-guided celiac plexus neurolysis in upper abdominal cancer patients: a randomized, prospective study for comparison of percutaneous bilateral paramedian vs. unilateral paramedian needle-insertion technique. Pain Pract 14(2):E63–E68. https://​doi.​org/​10.​1111/​papr.​12107CrossRefPubMed
25.
Zurück zum Zitat Vig S, Bhan S, Bhatnagar S (2021) Celiac plexus block—an old technique with new developments. Pain Physician 24(5):379–398PubMed Vig S, Bhan S, Bhatnagar S (2021) Celiac plexus block—an old technique with new developments. Pain Physician 24(5):379–398PubMed
28.
Zurück zum Zitat Dupoiron D, Duarte R, Carvajal G, Aubrun F, Eldabe S (2022) Rationale and recent advances in targeted drug delivery for cancer pain: is it time to change the paradigm? Pain Physician 25(3):E414–Ee25PubMed Dupoiron D, Duarte R, Carvajal G, Aubrun F, Eldabe S (2022) Rationale and recent advances in targeted drug delivery for cancer pain: is it time to change the paradigm? Pain Physician 25(3):E414–Ee25PubMed
34.
36.
Zurück zum Zitat Rosian K, Hawlik K, Piso R (2018) Efficacy assessment of radiofrequency ablation as palliative pain treatment in patients with painful metastatic spinal lesions: a systematic review. Pain Physician 21:E467–E476 Rosian K, Hawlik K, Piso R (2018) Efficacy assessment of radiofrequency ablation as palliative pain treatment in patients with painful metastatic spinal lesions: a systematic review. Pain Physician 21:E467–E476
37.
Zurück zum Zitat Gudugintta M (2006) Vertebroplasty: a new treatment for vertebral compression fractures. Aust Fam Physician 35(5):304–307 Gudugintta M (2006) Vertebroplasty: a new treatment for vertebral compression fractures. Aust Fam Physician 35(5):304–307
Metadaten
Titel
The use of interventional procedures for cancer pain. A brief review
verfasst von
Yi-Ching Lee
Timothy Brake
Emma Zhao
Alix Dumitrescu
Wei Lee
Benjamin Tassie
Kok-Eng Khor
Andy Yi-Yang Wang
Publikationsdatum
01.05.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 5/2024
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-024-08467-6

Weitere Artikel der Ausgabe 5/2024

Supportive Care in Cancer 5/2024 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.